Skip to Main Content

Can phone calls bring down drug prices? Do mom-and-pop investors have a prayer against hedge funds? And how do you know whether an Alzheimer’s drug actually works?

We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation about that mysterious phone call with President Trump that led Pfizer’s CEO to, at least briefly, lower some drug prices. Then we’ll talk to some biotech investors: one about the health skepticism surrounding Biogen’s latest Alzheimer’s study, and another about how retail stock-pickers can get a leg up on biotech’s investing incumbents.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!